ESMO 2016 Congress

Oncology Meeting Resources

07 Oct - 11 Oct, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search in ESMO 2016 presentation

 

Special Sessions and Tracks

Useful links

Presenter Presentation title Session title
Sjoerd van der Burg Back to the basics Cancer Immunotherapy (CIT): What every oncologist should know
Ignacio Melero Immune checkpoints: Do we really know how they work? Cancer Immunotherapy (CIT): What every oncologist should know
Inge-Marie Svane T cell therapy: For whom and when? Cancer Immunotherapy (CIT): What every oncologist should know
Ulrik Lassen Welcome to Copenhagen Opening Session and Award lectures - Followed by welcome refreshments
Andrés Cervantes ESMO 2016 Scientific address Opening Session and Award lectures - Followed by welcome refreshments
Alberto Sobrero ESMO Award lecture: The hard road to ranking the clinical benefit of antineoplastic drugs Opening Session and Award lectures - Followed by welcome refreshments
Richard Peto ESMO Lifetime Achievement Award lecture Opening Session and Award lectures - Followed by welcome refreshments
Dirk Arnold What can be done beyond first line targeted agents: Switch or continue? Metastatic colorectal cancer: Providing the continuum of care
Giuseppe Curigliano Unlocking the pathways of endocrine resistance New developments in the management of ER-positive metastatic breast cancer
Uwe Haberkorn The role of PET/CT Imaging in metastatic prostate cancer
Michael Morris Radiographic progression free survival: A new biomarker of response to treatment? Imaging in metastatic prostate cancer
Pieter Wesseling The new WHO classification: Is molecular diagnosis ready for prime time? Wind of change: Challenges in neuro-oncology in 2016
Michael Brada Standard and future approaches in the treatment of rare CNS tumours Wind of change: Challenges in neuro-oncology in 2016
Evandro de Azambuja Introduction Communication findings of clinical trials: The first 12 months from analysis
Annabelle South Disseminating results: What are we trying to achieve and who needs to hear? Communication findings of clinical trials: The first 12 months from analysis